secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-175433
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q2 net loss $37.2M ($0.44/shr); cash $379.7M; repurchases shares; strategic review ongoing
--------------------------------------------------------------------------------

- Net loss of $37.2M ($0.44 diluted EPS) vs $40.5M loss in Q2 2024; R&D expense $32.3M, down $2.4M YoY.
- Cash, equivalents and marketable securities $379.7M at June 30, 2025, down from $454.7M at Dec 31, 2024.
- Board authorized up to $25M share repurchase; 4.6M shares bought at avg $3.01 through June 30.
- Engaged Evercore to evaluate strategic alternatives including partnerships, M&A, or sale of assets.
- Global Phase 3 HCV program (C-BEYOND, C-FORWARD) enrolling on track; 98% SVR12 in Phase 2 per-protocol population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525175433/0001193125-25-175433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525175433/d921944d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-175433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer